CClinicalTrials.gg
Status unknownNCT01518114Updated Jan 31, 2012

Exercise Training in Patients With Hypertrophic Cardiomyopathy

An interventional study of Exercise Training in Hypertrophic Cardiomyopathy, sponsored by Sheba Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-31.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Exercise training (ET) is highly beneficial in heart failure patients and has been suggested to confer significant symptomatic and functional improvements in patients with diastolic dysfunction. Accordingly, the aim of this study was to examine the safety, feasibility of a structured ET program in symptomatic HCM patients.

02

Conditions studied

  • Hypertrophic Cardiomyopathy

Keywords

  • Hypertrophic Cardiomyopathy
  • Exercise Training
  • Cardiac Rehabilitation
  • Heart Failure
03

In context

Cardiomyopathies

1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.

This study's planned enrollment of 60 is above the median of 51 across 609 interventional studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Hypertrophic Cardiomyopathy
  • NYHA 3
  • Maximal left ventricular wall thickness > 20 mm
  • Age >18

Exclusion criteria

Exclusion Criteria:

  • Severe non-cardiac limitations of functional capacity such as neurological illness, lung disease, peripheral vascular or orthopedic problem, etc.
  • Patients state post resuscitation for malignant ventricular arrhythmia.
  • History of effort induced syncope, complex ventricular arrhythmia or atrial fibrillation.
  • An exercise-induced decrease in blood pressure
  • Severe left ventricular outflow obstruction defined as resting outflow gradient > 50 mmHg on maximal therapy
  • Atrial fibrillation with a poorly controlled ventricular response
  • Advanced hypokinetic stage of HCM defined as LVEF \< 40%
  • Congestive heart failure of angina FC IV according to NYHA or CCS respectively.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercise Training

    Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale. Exercise prescription will be based upon cardiopulmonary test done at baseline.

    Behavioral: Exercise Training

  • Active comparator
    Best Medical Care

    Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.

    Behavioral: Exercise Training

Interventions

  • BehavioralExercise Training

    Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.

06

What researchers measure

Primary outcomes

  1. Functional capacity improvement as determined by the degree of percent change in VO2 MAX following structured exercise rehabilitation

    End point to be assessed by cardiopulmonary testing are pre- and post exercise training improvement as expressed by the changes in : VO2 MAX, exercise duration, duration to ventilatory threshold(VT).

    Time frame: 6 months

  2. Safety of exercise training in patients with symptomatic hypertrophic cardiomyopathy

    Safety endpoonts: 1) Clinicaly significant arrhythmia during exercise training 2)MACE during follow-up period (ACS, Stroke or Death) 3)Exercise Related Injury 4) Episodes of syncope

    Time frame: 12 months

Secondary outcomes

  1. Secondary Endpoints:

    1. The effect on quality of life 2. The change in maximal wall thickness, LVEF, resting and exercise-induced left ventricular outflow gradient and pulmonary artery pressure (stress echo). 3. Resting BNP and troponin I levels

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Sheba Medical Center
    Tel Hashomer , Ramat Gan, Israel
    • Robert Klempfner, MD · Contact · klempfner@gmail.com · +972525506852
    • Arad Michael, MD · Principal investigator
    • Tamir Kamerman, MS · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01518114
Lead sponsor
Sheba Medical Center
Responsible party
Dr. Michael Arad (MD, Sheba Medical Center) — Principal investigator
First posted
Jan 25, 2012
Start date
Dec 2011
Primary completion
Jan 2013 (estimated)
Last update
Jan 31, 2012

Study contacts

Arad Michael, MD
Contact
Michael.Arad@sheba.health.gov.il
Robert Klempfner, MD
Contact
klempfner@gmail.com
+972525506852

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion